EUCTR2014-003144-12-DE进行中（未招募）不适用
A trial to compare the pharmacokinetics and pharmacodynamics of insulin lispro administered s.c. into lipohypertrophic or normal abdominal adipose tissue in subjects with diabetes mellitus type 1
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedures that would not have been performed during normal management of the subject).
- •2.Male or female subject with diabetes mellitus type 1.
- •3.Age between 18 and 64 years, both inclusive.
- •4.Body Mass Index (BMI) between 18.5 and 30 kg/m2, both inclusive.
- •5.HbA1c = 10%.
- •6.Negative C-peptide (= 0.30 nmol/L).
- •7.Total insulin dose of < 1.2 U/kg/day.
- •8.Diabetes duration of at least 3 years.
- •9.Stable insulin regimen (either multiple daily injection or insulin infusion pump) for at least 2 months prior to inclusion into the study, as judged by the investigator.
- •10.Presence of lipohypertrophic and non-lipohypertrophic adipose tissue at comparable sites, as confirmed by two independent investigators via physical examination and sonography.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 13
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1.Known or suspected hypersensitivity to trial product(s) or related products.
- •2.Previous participation in this trial. Participation is defined as randomised.
- •3.Receipt of any investigational medicinal product within 30 days before randomisation in this trial.
- •4.History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
- •5.Any history or presence of cancer except basal cell skin cancer or squamous cell skin cancer as judged by the investigator.
- •6.Any history or presence of clinically relevant cardiovascular, pulmonary, respiratory, gastrointestinal, hepatic, renal, metabolic, endocrinological (with the exception of conditions associated with diabetes mellitus), haematological, dermatological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynaecologic (if female), or infectious disease, or signs of acute illness as judged by the investigator.
- •7.Any serious systemic infectious disease during four weeks prior to first dosing of the study drug, as judged by the investigator.
- •8.Clinically significant abnormal lab results for haematology, clinical chemistry, or urinalysis as judged by the investigator.
- •9.Abnormalities in renal function (e.g. serum creatinine > 120 µmol/L for male, >100 µmol/L for female subjects) as judged by the investigator that would pose a problem of clearance of injected insulin.
- •10.Supine blood pressure at screening (after resting for at least 5 min in supine position) outside the ranges for systolic 95-140 mmHg blood pressure and for diastolic greater than 90 mmHg or symptoms and a heart rate at rest outside of 50-90 beats per minute (excluding white-coat hypertension; therefore, if a repeated measurement shows values within the range, the subject can be included in the trial). This exclusion criterion also pertains to subjects being on anti-hypertensives.
研究者
相似试验
进行中（未招募）
1 期
A research study of how fast-acting insulin aspart works in the body of children, young people and grown-ups with type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 20.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861EUCTR2017-002014-31-DEovo Nordisk A/S43
招募中
不适用
A study to compare the pharmacokinetics profile of DWCZP tablet 100mg and Clozaril® tablet 100mg.Mental and behavioral disordersKCT0000531Dong Hwa Pharm28
招募中
不适用
Clinical Trials to Compare the Pharmacokinetic Profiles of Sarpogrelate hydrochloride 300mg SR Tablet and ANPLAG® IR After Multiple Oral Administration to Healthy Male SubjectsKCT0000156Kunwha Pharmaceutical18
招募中
不适用
Clinical Trials to Compare the Pharmacokinetic Profiles of Sarpogrelate hydrochloride 300mg SR Tablet and ANPLAG® IR After Oral Administration to Healthy Male SubjectsKCT0000202Kunwha Pharmaceutical18
已完成
不适用
A bridging trial to compare the pharmacokinetics of Glepaglutide (ZP1848) after a single subcutaneous administration by vial/syringe and by autoinjector in healthy subjects: a phase 1, randomized, open-label, three-way, reference-replicated crossover trialBioequivalenceHealthy volunteersNL-OMON49360Zealand Pharma A/S72